Walless has advised UK healthcare company Everything Genetic on its EUR 500,000 investment into and strategic partnership agreement with Estonian health technology company Antegenes. Myerson Solicitors reportedly advised Everything Genetic on English law.
According to Walless, Everything Genetic is a market-leading genetic test brands distributor on the UK market, aiming to democratize genetic testing to healthcare providers and patients for the detection, diagnosis, and treatment of cancer, cardiac, and other illnesses.
Founded in 2018, Antegenes is a registered healthcare service provider of medical genetics, oncology, and laboratory services.
"Genetic testing for cancer has until now been the preserve of an exclusive few, only available in private clinics with costs running into the thousands, but this new investment into the Antegenes service will deliver a cost-effective way to bring down the cost of this novel tech," Everything Genetic CEO James Price commented.
"We are very excited for our strategic partnership with Everything Genetic for the wider application of our tests within the UK healthcare sector," added Antegenes CEO Peeter Padrik. "This is a historic step as we enter a new era of personalized cancer prevention. Most importantly, we have a clear shared vision of how innovative genetic solutions can help save lives and reduce the impact cancer has on our society."
The Walless team included Partner Hannes Vallikivi and Associate Kaisa Saarmann.